Overall market sentiment has been neutral on Crispr Therapeutics AG (CRSP) stock lately. CRSP receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,neutral
Crispr Therapeutics AG has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock is trading at $117.35 as of 10:40 AM on Thursday, May 20, an increase of $6.79, or 6.14% from the previous closing price of $110.56. The stock has traded between $112.04 and $118.02 so far today. Volume today is less active than usual. So far 344,254 shares have traded compared to average volume of 1,544,992 shares.

To see InvestorsObserver's Sentiment Score for Crispr Therapeutics AG click here.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.



Source link